Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 4/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4781429 | 0.82 | HTR6 (0.51) | HTR6SRCPTGER4KDM4E | |
| SCHEMBL24015624 | 0.81 | HTR6 (0.52) | PTGDR2PTGDRHTR6SRCACLY | |
| SCHEMBL25811424 | 0.81 | HTR6 (0.50) | PTGDR2PTGDRHTR6SRCACLY | |
| SCHEMBL25811425 | 0.80 | PTGDR2 (0.47) | PTGDR2PTGDRHTR6SRCACLY | |
| SCHEMBL19605706 | 0.79 | HTR6 (0.50) | PTGDR2PTGDRHTR6SRC | |
| SCHEMBL12803572 | 0.78 | BRD4 (0.47) | SRCACLYBRD4HDAC1HDAC2 | |
| SCHEMBL25811430 | 0.77 | PTGDR2 (0.51) | PTGDR2PTGDRHTR6SRCACLY | |
| SCHEMBL13464050 | 0.77 | PTGER4 (0.44) | PTGDR2PTGDRHTR6SRCBRD4 | |
| SCHEMBL25811422 | 0.76 | MAPT (0.57) | PTGDR2PTGDRHTR6SRCKDM4E | |
| SCHEMBL4775939 | 0.76 | HTR6 (0.51) | HTR6SRCPTGER4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | PTGDR2 4166/4885PTGDR 3816/4885HTR6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.